Facebook Instagram Twitter RSS Feed PodBean Back to top on side

Novel lncRNA-ZNF281 regulates cell growth, stemness and invasion of glioma stem-like U251s cells

In: NEOPLASMA, vol. 66, no. 1
Xt Li - Jc Li - M Feng - Yx Zhou - Zw Du
Detaily:
Rok, strany: 2019, 118 - 127
O článku:
Glioma is the most common sub-type of brain tumor. Due to the presence of stem-like cells, it is characterized by poor prognosis, aggressive ability and high post-surgical recurrence rates. Hence, there is critical need to identify molecular mechanisms of glioma stem-like cells. We found a novel lncRNA in the ZNF281 gene and named it lncRNA-ZNF281. We detected the expression of lncRNA-ZNF281 in glioma stem-like cells (U251s), the glioma cell line (U251) and also in normal brain tissue. The expression of lncRNA-ZNF281 was lower in glioma stem-like cells (U251s) and this indicates that lncRNA-ZNF281 can regulate the self-renewal capacity of glioma stem-like cells and stem cell marker expression. Most significantly, lncRNA-ZNF281 inhibits the invasion of glioma stem-like cells by regulating the expression of the NF-κB1 signaling pathway. Our data demonstrates that lncRNA-ZNF281 inhibits the self-renewing ability and invasion of GSCs in vitro and in vivo and can reduce tumorigenicity in the glioma stem-like cell (U251s). The underlying mechanisms may involve the regulation of stem cell markers (CD133, Nestin, OCT4 and Nanog) to reduce the self-renewal ability and regulate the NF-κB1 signaling pathway and inhibit U251s glioma stem-like cell invasion. These finding suggest that lncRNA-ZNF281 could be a successful new therapeutic target in glioma.
Ako citovať:
ISO 690:
Li, X., Li, J., Feng, M., Zhou, Y., Du, Z. 2019. Novel lncRNA-ZNF281 regulates cell growth, stemness and invasion of glioma stem-like U251s cells. In NEOPLASMA, vol. 66, no.1, pp. 118-127. 0028-2685.

APA:
Li, X., Li, J., Feng, M., Zhou, Y., Du, Z. (2019). Novel lncRNA-ZNF281 regulates cell growth, stemness and invasion of glioma stem-like U251s cells. NEOPLASMA, 66(1), 118-127. 0028-2685.